Literature DB >> 2202477

Pretreatment with rh-GMCSF, but not rh-IL3, enhances PAF-induced eosinophil accumulation in guinea-pig airways.

S Sanjar1, D Smith, M A Kings, J Morley.   

Abstract

Intraperitoneal injections of recombinant human granulocyte-macrophage colony stimulating factor (rh-GMCSF, 50 micrograms/kg-1 daily) or interleukin-3 (rh-IL3, 50 micrograms kg-1 daily) for two days, induced an increase in the percentage of bone marrow and pulmonary airway eosinophils in the guinea-pig. In addition, rh-IL3-treated animals exhibited an increase (21%) in blood neutrophils. Exposure of guinea-pigs to an aerosol of platelet activating factor (PAF) gives rise to a selective pulmonary eosinophil accumulation, maximal at 48 h. The eosinophilic response to PAF was significantly enhanced in rh-GMCSF-treated guinea-pigs but was suppressed in rh-IL3-treated animals.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2202477      PMCID： PMC1917787          DOI： 10.1111/j.1476-5381.1990.tb15817.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  8 in total

1.  Eosinophil accumulation in pulmonary airways of guinea-pigs induced by exposure to an aerosol of platelet-activating factor: effect of anti-asthma drugs.

Authors:  S Sanjar; S Aoki; K Boubekeur; I D Chapman; D Smith; M A Kings; J Morley
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

2.  Early and late-phase bronchoconstriction after allergen challenge of nonanesthetized guinea pigs. I. The association of disordered airway physiology to leukocyte infiltration.

Authors:  P A Hutson; M K Church; T P Clay; P Miller; S T Holgate
Journal:  Am Rev Respir Dis       Date:  1988-03

3.  Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease.

Authors:  P C Tai; S J Ackerman; C J Spry; S Dunnette; E G Olsen; G J Gleich
Journal:  Lancet       Date:  1987-03-21       Impact factor: 79.321

Review 4.  The eosinophil and the pathophysiology of asthma.

Authors:  E Frigas; G J Gleich
Journal:  J Allergy Clin Immunol       Date:  1986-04       Impact factor: 10.793

5.  Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration. Modulation by prostacyclin, platelet depletion, and selective antagonists.

Authors:  A Lellouch-Tubiana; J Lefort; M T Simon; A Pfister; B B Vargaftig
Journal:  Am Rev Respir Dis       Date:  1988-04

6.  Skin eosinophilia in atopic patients.

Authors:  E Henocq; B B Vargaftig
Journal:  J Allergy Clin Immunol       Date:  1988-04       Impact factor: 10.793

7.  Leukotriene production in human neutrophils primed by recombinant human granulocyte/macrophage colony-stimulating factor and stimulated with the complement component C5A and FMLP as second signals.

Authors:  C A Dahinden; J Zingg; F E Maly; A L de Weck
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

8.  Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts.

Authors:  W F Owen; M E Rothenberg; D S Silberstein; J C Gasson; R L Stevens; K F Austen; R J Soberman
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307
  8 in total
  3 in total

1.  Effect of murine recombinant interleukin-5 on the cell population in guinea-pig airways.

Authors:  T Iwama; H Nagai; H Suda; N Tsuruoka; A Koda
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  Effect of human recombinant interleukin-5 on in vitro responsiveness to PAF of lung from actively sensitized guinea-pigs.

Authors:  M Pretolani; J Lefort; D Leduc; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

3.  Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells.

Authors:  L Churchill; B Friedman; R P Schleimer; D Proud
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.